Metabolic syndrome in french HIV-infected patients: Prevalence and predictive factors after 3 years of antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 28, Issue 12, 2012, Pages 1672-1678

  Biron, Antoine ^a   Bobin Dubigeon, Christine ^b   Volteau, Christelle ^a   Piroth, Lionel ^c   Perré, Philippe ^d   Leport, Catherine ^e   Prazuck, Thierry ^f   Jovelin, Thomas ^a   Billard, Martine ^a   Sébille, Veronique ^a,g   Bard, Jean Marie ^b   Raffi, François ^a   Biron, Charlotte ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d Departmental Hospital   (France)

^e Bichat University   (France)

^f Hospital Porte Madeleine   (France)

^g Universite de Nantes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; C REACTIVE PROTEIN; EMTRICITABINE; FOSAMPRENAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIET RESTRICTION; FEMALE; FRANCE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIXED INFECTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; HIV INFECTIONS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84870023846     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0048     Document Type: Article

References (38)

1. Pasternak R: Adult Treatment Panel II versus Adult Treatment Panel III: What has changed and why? Am J Cardiol 2002;89(5A):3C-7C.
2. Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, and Can G: Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: A prospective cohort study. Atherosclerosis 2007;191(1):182-190.
3. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24(4):683-689.
4. Haffner SM, Mykkanen L, Festa A, Burke JP, and Stern MP: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state. Circulation 2000;101(9):975-980.
5. Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853-860.
6. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al.: A syndrome of peripheral lipodystrophy, hyperli-pidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12(7):F51-58.
7. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, and Cooper DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999;353(9170):2093-2099.
8. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al.: Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010; 24(8):1228-1230.
9. Samaras K, Wand H, Law M, Emery S, Cooper D, and Carr A: Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007;30(1):113-119.
10. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costa-gliola D, et al.: Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008;48(5):590-598.
11. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al.: Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201(3):318-330.
12. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al.: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet 2008;371(9622):1417-1426.
13. Jovinge S, Hamsten A, Tornvall P, Proudler A, Bavenholm P, Ericsson CG, et al.: Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 1998;47(1):113-118.
14. Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Rosella E, Franzetti M, et al.: HIV and metabolic syndrome: A comparison with the general population. J Acquir Immune Defic Syndr 2007;45(4):426-431.
15. Grundy SM: A constellation of complications: the metabolic syndrome. Clin Cornerstone 2005;7(2-3):36-45.
16. Onat A, Hergenc G, Sansoy V, Fobker M, Ceyhan K, Toprak S, et al.: Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 2003;168(1):81-89.
17. Kahn R, Buse J, Ferrannini E, and Stern M: The metabolic syndrome: Time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005;48(9):1684-1699.
18. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, et al.: Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007;21(18):2445-2453.
19. Garin MC, Kalix B, Morabia A, and James RW: Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrinol Metab 2005; 90(4):2264-2269.
20. Jerico C, Knobel H, Montero M, Ordonez-Llanos J, Guelar A, Gimeno JL, et al.: Metabolic syndrome among HIV-infected patients: Prevalence, characteristics, and related factors. Diabetes Care 2005;28(1):132-137.
21. Bard JM, Lassalle R, Capeau J, Bach-Ngohou K, Nazih-Sanderson F, Remy G, et al.: Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy. Antivir Ther 2006;11(3):361-370.
22. Murata H, Hruz PW, and Mueckler M: The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275(27):20251-20254.
23. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, et al.: Association between altered expression of adipo-genic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002;359(9311):1026-1031.
24. The SMART/INSIGHT and the D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22(14): F17-24.
25. Schafer JJ, Short WR, and Squires KE: Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus. Pharmacotherapy 2010;30(10):1072-1083.
26. Martinez E, Larrousse M, Podzamczer D, Perez I, Gutierrez F, Lonca M, et al.: BICOMBO Study Team. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 2010;24:F1-9.
27. Martin A, Amin J, Cooper DA, Carr A, Kelleher AD, Bloch M, et al.: Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: A randomized clinical trial. AIDS 2010;24:2657-2663.
28. Cruciani M, Zanichelli V, Serpelloni, Bosco O, Malena M, Mazzi R, et al.: Abacavir use and cardiovascular disease events: A meta-analysis of published and unpublished data. AIDS 2011;25:1993-2004.
29. Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al.: Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003;349:1036-1046.
30. Ross R: Atherosclerosis is an inflammatory disease. Am Heart J 1999;138(5 Pt 2):S419-420.
31. Luc G, Bard JM, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, et al.: C-reactive protein, interleukin-6, and fi-brinogen as predictors of coronary heart disease: The PRIME Study. Arterioscler Thromb Vasc Biol 2003;23(7):1255-1261.
32. Ridker PM, Buring JE, Cook NR, and Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107(3):391-397.
33. Ettinger WH, Varma VK, Sorci-Thomas M, Parks JS, Sigmon RC, Smith TK, et al.: Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler Thromb 1994;14(1):8-13.
34. Guimaraes MM, Greco DB, Figueiredo SM, Foscolo RB, Oliveira AR, Jr, and Machado LJ: High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection. Atherosclerosis 2008;201(2):434-439.
35. De Castro IF, Micheloud D, Berenguer J, Guzman-Fulgencio M, Catalan P, Miralles P, et al.: Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients. AIDS 2010; 24(13):2059-2067.
36. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, and Saag M: Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 2010;11(7):462-468.
37. Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, and Chiodo F: Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res 2008; 6(6):572-578.
38. Aslangul E, Assoumou L, Bittar R, Valantin MA, Kalmykova O, Peytavin G, et al.: Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: A randomized trial. AIDS 2010;24(1):77-83.